Adjuvant TKI therapy in resected
EGFR
-mutant non-small-cell lung cancer-ready for prime time?
Transl Lung Cancer Res
.
2020 Oct;9(5):1728-1731.
doi: 10.21037/tlcr-20-615.
Authors
Surein Arulananda
1
,
Thomas John
2
3
Affiliations
1
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
2
Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Australia.
3
Department of Medicine, University of Melbourne, Parkville, Australia.
PMID:
33209595
PMCID:
PMC7653106
DOI:
10.21037/tlcr-20-615
No abstract available
Publication types
Editorial
Comment